Mike King at IQVIA reveals why digital quality documentation is deemed a key enabler in advanced therapy sectors, increasingly influencing how sponsors select manufacturers.

Regulatory oversight of pharmaceutical quality systems has tightened steadily over the past several years, and few areas illustrate that shift as clearly as documentation practice. The European Commission’s revision of Chapter 4 of the EU GMP guide,1 which sets out expectations for document control, is part of this trend: auditors want regulated organisations to build data integrity principles (attributable, legible, contemporaneous, original, accurate – the familiar ALCOA+ framework) into day-to-day document creation and record keeping – not cobble them together when inspections loom.
However, while clean records are a baseline for inspection readiness across pharmaceutical manufacturing, advanced therapy sectors – such as cell and gene therapy, mRNA and plasmid DNA for viral vector manufacturing – face a scaling problem that adds urgency to digital readiness. It’s not uncommon for organisations in these fields to maintain hundreds to thousands of active standard operating procedures (SOPs), analytical methods, specifications, quality agreements and more at any given time. Each must be periodically reviewed and redistributed; each signature on each page must be verified. When that library isn’t managed electronically – or, as is increasingly common, in hybrid paper/digital systems that were never designed for the pace or depth of current inspections – staying ‘audit ready’ isn’t a background task. In practice, it represents a recurring burden on quality-team capacity and can reduce the time available for the professional activities they were hired to execute.
‘Quality maturity’ as a value proposition
The ‘why’ of digital quality does not begin and end with regulatory expectation. ICH Q9(R1)2 and Q103 both frame risk management and pharmaceutical quality systems as foundational, proactive practices, not checkboxes to tick on an annual renewal schedule. For contract development and manufacturing organisations (CDMOs), and increasingly for biotech manufacturing organisations (BMOs) active in advanced therapy medicinal product sectors, another value proposition is emerging alongside regulatory compliance as a driver for digital quality: the ability to demonstrate quality-system maturity is increasingly influencing how sponsors choose and retain manufacturers.
The ‘why’ of digital quality does not begin and end with regulatory expectation.”
Imagine the diligence process from a sponsor’s point of view. In addition to certifications and attestations, manufacturers must be able to show – quickly and on demand – that training records are up to date and that documents are current, controlled and accessible across the quality team. If quality information is siloed in spreadsheets or locked within paper folders stored in physical filing cabinets, due diligence becomes a bottleneck. By contrast, a digitally enabled quality system with a robust audit trail becomes something else: a demonstration of readiness that begins at first client contact.
A case in point
Anemocyte,4 an Italian BMO with more than 25 years of good manufacturing practice (GMP) experience in cell and gene therapies and biological drugs – with current work spanning mRNA for vaccines and immuno-oncology therapies, and plasmid DNA for viral vector and RNA manufacturing – illustrates both sides of this shift.
The company has been certified to ISO 9001 since 2000 and cGMP since 2004, with filings under FDA-GMP regulations since 2006. The company had reached a point where its long-standing paper-based quality system was becoming a constraint rather than a support. Managing 800 to 1,000 active SOPs and work instructions, the quality team faced days of manual document retrieval before every audit, no real-time visibility into training completion and KPI reporting that depended entirely on manual compilation.
“We had a company commitment to become more efficient, but there was also the question of how we demonstrate to our clients that our quality management system is robust,” said Giuseppe Aruanno, Quality Assurance Manager at Anemocyte. Internally, the company described the underlying problem as one of information moving on “a single, isolated track” – a paper system that had functioned adequately for years but could not connect processes or scale with the business.
What changed, and how
The implementation of IQVIA’s new electronic quality management system began with a process audit and an agreement not to attempt to recreate Anemocyte’s existing paper-centric system digitally. “We decided to rebuild the architecture,” Aruanno said. Rather than mapping and translating existing workflows into electronic equivalents, the company took the opportunity to re-examine the module structure of its documents directly – splitting modules from SOPs that had been combined and updating processes, not to mirror paper workflows but to align with sector best practice.
Document types were introduced in a deliberately staged sequence – SOPs and analytical methods first, followed by release specifications, then quality agreements, with additional document categories added as the organisation gained familiarity with the system. The full migration ran across roughly eight months of implementation and two more months of monitoring supported by the equivalent of 1.5 dedicated internal full-time resources. Validation effort was concentrated on Anemocyte’s site-specific configuration – document numbering conventions and review hierarchies, for instance – rather than requalifying already-validated core system modules, a risk-based approach consistent with where computer system validation practice in the sector has been heading.
Measurable outcomes that live beyond audit season
Following implementation, the most immediately visible result was that the lead time for document preparation and annual audit readiness cycles improved by about 90 percent, including document retrieval time on the manufacturing floor. Signatures can now be captured directly via tablets on the manufacturing floor, eliminating the need to track down employees who may no longer be stationed at their ‘wet signature’ location. By Anemocyte’s calculation, this freed up the equivalent of the continuous effort of four to five full-time employees based on approximately eight hours of document processing across their SOP library on an annual cycle.
In addition to cycle time, the elimination of uncontrolled paper copies within the organisation, replaced by a single verified source of the current document version, is a data integrity benefit that may ultimately supersede raw efficiency. Training records now carry full, automatically updated traceability at the individual level, giving quality managers real-time visibility into completion status rather than reconstructing it ahead of each audit. This shift away from paper has a secondary sustainability effect of reduced dependence on printing, toner and associated disposal costs.
“Inspection readiness has become a real competitive advantage for us,” Aruanno said. “We can retrieve our SOPs and documents in a couple of clicks instead of searching manually, and preparation before an inspection is now very fast.” The company reports that time previously lost to physically transporting binders to an inspection room or searching for the correct document version has been effectively eliminated, with information retrievable on screen during the audit itself.
A broader pattern
Anemocyte’s experience reflects a pattern now visible more widely across CDMOs and BMOs. Organisations are reframing inspection readiness from a recurring cost centre into a business asset that can help companies stand out when a sponsor is deciding where to manufacture their next drug or device. The organisations moving fastest on this front aren’t always the largest but rather the ones that recognise that a transparent, real-time quality system is quickly becoming table stakes for winning and retaining sponsor business, not just an exercise in regulatory obligation and passing inspections.
Organisations are reframing inspection readiness from a recurring cost centre into a business asset that can help companies stand out when a sponsor is deciding where to manufacture their next drug or device.”
Another effect also deserves attention. When quality data need not be manually compiled, it can be used to drive continuous improvement rather than exist solely to feed static compliance reports. This KPI benefit is often underrated, as once a team is free from compiling those reports they can use their gained time to interrogate data and drive actionable insights that fundamentally improve process and product quality.
A final note on change management
This shift is not a purely technological one. The value realised at Anemocyte resulted equally from how the migration was run. The phased, risk-based rollout enabled the organisation to gradually build familiarity with the system facilitating the deliberate decision to restructure document architecture rather than digitalise existing inefficiencies.
That distinction is worth underlining for an industry watching this trend from the outside. Digitalising a quality system is not simply an IT project; it requires an organisation to interrogate the process logic underneath its documentation, from hierarchy and sign-off routing to training assignments, before any efficiency gain can be realised. Done deliberately, as Anemocyte’s experience suggests, the result is not only faster audit preparation but a more resilient quality infrastructure capable of supporting the level of scrutiny and scale of growth that increasingly define competitiveness in advanced therapy manufacturing. Ultimately, all of these benefits pull through to improving company process and product quality, which, in turn, have a direct impact in improving the provision of safe and effective patient solutions.
References
1. Chapter 4: Documentation - EU GMP. [Internet] European Commission. Available from: https://health.ec.europa.eu/document/download/fa336a6e-753b-46fc-b53b-9178bacd8878_en?filename=mp_vol4_chap4_consultation_guideline_en.pdf
2. ICH Q9(R1) Quality Risk Management – Guidance for Industry. [Internet] FDA. 2023. Available from: https://www.fda.gov/media/167721/download
3. Guidance Document – Q10 Pharmaceutical Quality System. [Internet] FDA. 2009. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q10-pharmaceutical-quality-system
4. [Internet] Anemocyte. Available from: https://anemocyte.com/
About the author
Mike King is Senior Director, Product & Strategy (Quality, Regulatory, Safety & Detect), Digital Products & Solutions at IQVIA. He is particularly focused on optimising business workflows through intelligence-driven simplification and automation within and across safety, regulatory and quality functions. Michael has nearly 20 years of knowledge and experience leading localised and global teams in regulatory affairs and quality assurance.



No comments yet